AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
AbCellera (Nasdaq: ABCL) will present at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8 to 12, 2022. The company’s VP of Translational Research, Bo Barnhart, emphasized the potential of T-cell engagers in oncology, highlighting advances in their CD3 panel and T-cell engager program. The presentation titled 'Streamlining T-cell engager development' is scheduled for November 11, showcasing AbCellera's bispecific engineering technology aimed at overcoming challenges in cancer treatment.
- Presentation at a significant industry meeting may enhance visibility and credibility.
- Focus on T-cell engagers highlights innovative approaches in precision oncology.
- None.
“T-cell engagers have tremendous potential as precision oncology therapeutics by redirecting cancer-killing T cells to specific tumor targets,” said
AbCellera’s T-Cell Engager Presentation:
Title: Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine
Poster Number: 1196
Date and Time:
Location:
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005054/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What will AbCellera present at the SITC Annual Meeting in 2022?
When is AbCellera's presentation scheduled?
What is the focus of AbCellera's presentation at the SITC Meeting?
Where can I find more information about AbCellera's presentation?